Large Polyglutamine Repeats Cause Muscle Degeneration in SCA17 Mice  by Huang, Shanshan et al.
ArticleLarge Polyglutamine Repeats Cause Muscle
Degeneration in SCA17 MiceGraphical AbstractHighlightsd A large polyQ repeat in TBP causes primary muscle
degeneration
d The severity of muscle degeneration is polyQ-number
dependent
d Different polyQ numbers differentially affect TBP’s interaction
with NF-YA and MyoD
d Impaired transcriptional activity of MyoD underlies muscle
degeneration in SCA17Huang et al., 2015, Cell Reports 13, 196–208
October 6, 2015 ª2015 The Authors
http://dx.doi.org/10.1016/j.celrep.2015.08.060Authors
ShanshanHuang, SuYang, JifengGuo, ...,





Huang et al. find that a large
polyglutamine repeat in TATA-box-
binding protein causes preferential
muscle degeneration in a knockin mouse
model of spinocerebellar ataxia 17.
Muscle degeneration is caused by
reduced expression of muscle-specific
genes, which resulted from an impaired
association of TBP with MyoD, a muscle-
specific transcription factor.Accession NumbersGSE72176
Cell Reports
ArticleLarge Polyglutamine Repeats Cause
Muscle Degeneration in SCA17 Mice
Shanshan Huang,1,2,4 Su Yang,1,4 Jifeng Guo,1 Sen Yan,1,3 Marta A. Gaertig,1 Shihua Li,1,* and Xiao-Jiang Li1,3,*
1Department of Human Genetics, Emory University School of Medicine, 615 Michael Street, Room 355, Atlanta, GA 30322, USA
2Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430032, China
3State Key Laboratory of Molecular Developmental Biology, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences,
Beijing 10010, China
4Co-first author
*Correspondence: sli@emory.edu (S.L.), xjli@genetics.ac.cn (X.-J.L.)
http://dx.doi.org/10.1016/j.celrep.2015.08.060
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).SUMMARY
In polyglutamine (polyQ) diseases, large polyQ re-
peats cause juvenile cases with different symptoms
than those of adult-onset patients, who carry smaller
expanded polyQ repeats. The mechanisms behind
the differential pathology mediated by different
polyQ repeat lengths remain unknown. By studying
knockin mouse models of spinal cerebellar ataxia-
17 (SCA17), we found that a large polyQ (105 gluta-
mines) in the TATA-box-binding protein (TBP)
preferentially causes muscle degeneration and re-
duces the expression of muscle-specific genes.
Direct expression of TBPwith different polyQ repeats
in mouse muscle revealed that muscle degeneration
is mediated only by the large polyQ repeats. Different
polyQ repeats differentially alter TBP’s interaction
with neuronal and muscle-specific transcription fac-
tors. As a result, the large polyQ repeat decreases
the association of MyoD with TBP and DNA pro-
moters. Our findings suggest that specific alterations
in protein interactions by large polyQ repeats may
account for the unique pathology in juvenile polyQ
diseases.
INTRODUCTION
Polyglutamine (polyQ) expansion causes at least nine inherited
neurodegenerative disorders, including Huntington’s disease
(HD), spinocerebellar ataxia (SCA) types 1, 2, 3, 6, 7, and 17, den-
tatorubral-pallidoluysian atrophy (DRPLA), and spinal bulbar
muscular atrophy (SBMA) (Orr and Zoghbi, 2007). Studies of
various polyQ disease proteins have shown that expanded
polyQ tracts affect the function of the disease proteins, leading
to a gain or loss of function (Lim et al., 2008). It is also clear
that the function of polyQ proteins can impact disease severity
and progression. For example, SCA17, which is caused by polyQ
expansion in the TATA-box-binding protein TBP, a transcription
factor essential for the transcription of a wide range of genes
(Vannini and Cramer, 2012), is associated with more severe196 Cell Reports 13, 196–208, October 6, 2015 ª2015 The Authorsneurological phenotypes than in other polyQ diseases, despite
the fact that the repeat in mutant TBP is often shorter than 64Q
(van Roon-Mom et al., 2005). In addition, different polyQ dis-
eases display distinct pathology. For example, SBMA is charac-
terized by muscle atrophy (Cortes et al., 2014; Lieberman et al.,
2014), which is reported to be moderate or absent in other polyQ
diseases.
The selectivity of polyQ toxicity apparently comes from protein
context, because it determines protein-protein interactions, half-
life and stability, subcellular localization, etc. However, the
length of the polyQ repeat also seems to modulate the selectivity
of polyQ protein toxicity. There is strong evidence that in HD,
polyQ repeats larger than 60 glutamines cause juvenile cases
that display different symptoms and more widespread degener-
ation in the brain. For example, juvenile HD patients do not
display chorea, but they have severe cognitive dysfunction and
seizure that is absent in adult HD patients (Vargas et al., 2003;
Squitieri et al., 2006). Juvenile HD patient brains also have
more nuclear aggregates, whereas adult HD brains have more
neuripil aggregates, also suggesting that polyQ lengths mediate
different pathogenic pathways (DiFiglia et al., 1997; Gutekunst
et al., 1998). Despite the well-known phenomenon of differential
pathology and symptoms in early- and adult-onset polyQ dis-
eases, the mechanism underlying this phenomenon has not
been investigated rigorously, and understanding it is critical if
we are to develop effective therapies for polyQ diseases.
SCA17 is a good candidate for investigating the mechanism
behind the cell-type-specific pathology in polyQ disease. The
CAG repeat in the normal human TBP gene ranges from 30 to
42 units. Expansion of the polyQ tract (>42 glutamines) in TBP in-
duces striking clinical features in SCA17 patients, including
ataxia, dystonia, parkinsonism, dementia, and seizures (Bruni
et al., 2004; Koide et al., 1999; Nakamura et al., 2001; Rolfs
et al., 2003). Marked cerebellar atrophy and Purkinje cell loss
are typical in SCA17 patients, with less pronounced neurode-
generation occurring in other brain regions (Bruni et al., 2004;
Koide et al., 1999; Nakamura et al., 2001; Rolfs et al., 2003;
Toyoshima et al., 2004; Bauer et al., 2004). However, when
polyQ repeats exceed 63Q, mutant TBP induces juvenile symp-
toms, with retarded growth and muscle weakness characterized
by impaired laryngeal and sphincter muscle function that results
in difficulties in swallowing, talking, and walking, as well as a
quick progression of clinical symptoms and early death (Koide
et al., 1999; Maltecca et al., 2003). These symptoms are clearly
different from those seen in adult-onset SCA17 patients.
We have established SCA17 knockin (KI) mice that express
one copy of mutant Tbp with 105Q under the control of Cre
recombination. We found that this large polyQ repeat in mutant
TBP leads to muscle degeneration, which was verified by selec-
tive expression of mutant TBP in muscle. Different polyQ repeat
lengths lead to different effects on the interactions of TBP with
neuronal and muscle-specific transcription factors. A large
(105Q) polyQ repeat decreases the association of TBP with
MyoD, a muscle-specific transcription factor (Tapscott, 2005;
Guttridge et al., 2000; Di Marco et al., 2005), reducing its stability
and association with DNA promoters. Our findings give usmech-
anistic insight into the unique pathology caused by large polyQ
repeats in polyQ diseases.
RESULTS
Mutant TBP Preferentially Accumulates in the Brain and
Muscle in SCA17 Knockin Mice
We previously established conditional TBP KI mice that express
mutant TBP specifically in the brain (Huang et al., 2011). In these
KI mice, a stop codon was placed in the front of the translation
initiation site for a mutant Tbp gene containing 105 CAGs. This
stop codon is flanked by two loxP sites, so it can be removed
by Cre to allow expression of mutant TBP. To generate SCA17
KImice that expressmutant TBP ubiquitously at the endogenous
level, we crossed floxed SCA17 KI mice with transgenic mice ex-
pressing Cre under the control of the EIIa promoter, which drives
the expression of Cre in early embryonic cells (Lakso et al., 1996;
Holzenberger et al., 2000). Floxed male SCA17 KI mice contain-
ing the Ella-Cre gene were mated with wild-type (WT) female
mice. The offspring mice were then genotyped to identify those
expressing mutant TBP, which should be derived from the
depletion of loxP sites or expression of the mutant Tbp allele at
the one-cell stage. F1 male mice expressing the mutant TBP
were then mated with WT female mice (B6) to generate F2
mice, which carry the mutant Tbp gene without the EIIa-Cre
gene. Such KI mice express one copy of WT Tbp and one
copy of mutant Tbp in an inherited manner identical to that
seen in SCA17 patients, in whommutant TBP is ubiquitously ex-
pressed (Figure 1A).
To confirm that mutant TBP is expressed in the brain and pe-
ripheral tissues in SCA17 KImice, we performedwestern blotting
analysis with two antibodies: anti-TBP (1TBP18), which can
recognize aggregated TBP in the stacking gel (Figure 1B, upper
panel), and 1C2, which reacts more strongly with the soluble
form of expanded polyQ proteins (Figure 1B, middle panel).
Expression of mutant TBP reduces the level of endogenous
TBP (arrow in Figure 1B), as also happened in earlier TBP trans-
genic and KI mouse brains (Friedman et al., 2007, 2008; Yang
et al., 2014). To verify that this indeed occurs in muscle tissue,
we immunoprecipitated TBP from WT and KI mouse muscle tis-
sues and found that the presence of mutant TBP also reduced
the level of WT TBP in themuscle (Figure S1A). RT-PCR revealed
that this decrease is associated with a decrease in endogenous
mouse TBP transcripts (Figure S1B). Thus, the expression levelCof TBP is tightly regulated at the transcriptional level because
of its critical function in gene transcription.
In SCA17 KI mice, soluble mutant TBP is present in the brain
(cerebellum, cortex) and peripheral tissues (muscle, liver, heart).
Importantly, aggregated TBP (bracket in Figure 1B), which re-
mains in the stacking gel, is present in the brain tissues and
also inmuscle, whereas liver and heart tissues, although they ex-
press soluble mutant TBP, do not show such aggregated TBP
(Figure 1B). We then analyzed the expression of mutant TBP in
the muscle tissues of SCA17 KI mice at different ages and found
that aggregated TBP accumulates in aged muscle, which is
evident by the more abundant aggregated TBP in the stacking
gel containing muscle proteins from the older SCA17 KI mice
(3 and 8 months) (Figure 1C).
We also performed immunocytochemical analysis to examine
the distribution of mutant TBP in the brain and muscle. Mutant
TBP is widely expressed in various brain regions, including the
cerebellum, brain stem, striatum, and hippocampus, and high
magnification reveals that mutant TBP forms small aggregates
in the nucleus (Figure 1D). Similarly, mutant TBP also accumu-
lates in the nuclei of skeletal muscle cells and forms small aggre-
gates (Figure 1E). Overall, we see that mutant TBP preferentially
accumulates in the nuclei of brain and muscle tissues in SCA17
KI mice.
Mutant TBP in Muscle Causes Degeneration
Gait abnormalities and muscle weakness are seen in some
SCA17 patients (Koide et al., 1999; Rolfs et al., 2003). The distri-
bution of mutant TBP in muscle cells led us to examine whether
mutant TBP could cause muscle pathology. H&E staining of
muscle tissues revealed normal morphology in the skeletal mus-
cle tissues of WT mice, viewed as well-defined muscle cells in
which the nuclei are localized peripherally. At 1.5 months of
age, SCA17 KI mice showed no distinguishable differences in
muscle morphology from WT mice (Figure S2A). However, mus-
cle degeneration was seen in SCA17 KI mouse skeletal muscle
sections at 3 months of age and became more severe at
7 months; this degeneration was characterized by uneven H&E
staining, fragmented muscle morphology, andmore importantly,
multiple internalized or centralized nuclei, a feature of muscle
cells regenerated after degeneration (Figure 2A). Quantitation
of muscle cross-sections also verified the degeneration of mus-
cle cells in SCA17 KI mice (Figure 2B). This degeneration ap-
pears to be specific to the skeletal muscle in SCA17 KI mice,
since cardiomyocytes, another type of muscle cell, showed no
differences in their morphology between SCA17 KI and WT
mice at 3 months of age (Figure S2B). Furthermore, we per-
formed electron microscopy (EM) studies that revealed typical
degeneration changes in the muscle cells of SCA17 mice. These
changes include intrafiber Z-band breaks, poorly aligned fibers
of themyofibrils, enlargedmitochondria, and swollen spaces be-
tween individual muscle cells in cross-sections (Figure 2C). Lon-
gitudinal sections also showed degenerated muscle cells in
SCA17 mice, as evidenced by disorganized muscle fibers,
frequent Z-band destruction, and sarcomere disruption, as well
as enlarged and swollen mitochondria (Figure 2C).
SCA17 is known to have a significant impact on the viability of
Purkinje cells in the cerebella of patients (Koide et al., 1999;ell Reports 13, 196–208, October 6, 2015 ª2015 The Authors 197
Figure 1. Mutant TBP Preferentially Accu-
mulates in Brain and Muscle in KI Mice
(A) The schematic structure of the targeted mouse
Tbp gene, which has a stop codon and the
neomycin (Neo) resistance gene flanked by two
loxP sites to prevent the translation of the mutant
Tbp gene. After EIIa Cre recombination, the stop
codon and Neo resistance gene are removed,
leading to the expression of the mutant Tbp gene
with 105 CAGs.
(B) Western blot of cerebellum (Cere), cortex (Ctx),
muscle, liver, and heart lysates from SCA17 KI (KI)
and wild-type (WT) mice at postnatal day 30 (P30).
The upper panel shows the blot probed with
1TBP18 antibody, which is against N-terminal
TBP. The middle panel shows the blot probed with
1C2 antibody, which is against expanded poly-
glutamine. The bottom panel shows the same blot
probed with g-tubulin. Arrow indicates endoge-
nous mouse TBP. Arrowhead indicates soluble
mutant TBP.
(C) Western blot of muscle lysates from KI and WT
mice at indicated ages. The blot was probed with
1TBP18 (upper panel) and anti-gapdh (lower
panel). Aggregated (bracket) mutant TBP proteins
are indicated.
(D) 1TBP18 immunostaining showing the selective
expression of mutant TBP in the cerebellum,
brainstem, hippocampus, cortex, and striatum of
3-month-old KI mouse brain. 1TBP18 at the same
concentration did not label the WT cerebellum.
Arrow indicates small nuclear aggregates in Pur-
kinje cells at high-power magnification. Scale bar,
10 mm (633 objective).
(E) 1TBP18 immunostaining showing the expres-
sion of mutant TBP in 3-month-old KI mouse
muscle. WT mouse muscle served as a control.
Scale bar, 50 mm.Nakamura et al., 2001; Rolfs et al., 2003; Bauer et al., 2004; Bruni
et al., 2004; Toyoshima et al., 2004). The striking pathology in
SCA17 KI muscle cells raises the important issue of whether
this degeneration results from the degeneration of the CNS,
which controls muscle viability and activity. It is possible that
mutant TBP might affect the neuromuscular junction (NMJ),
which then results in reduced muscle activity and muscle atro-
phy. We therefore examined the ultrastructure of the NMJ using198 Cell Reports 13, 196–208, October 6, 2015 ª2015 The AuthorsEM. EM examination revealed SCA17
mice had normal NMJmorphology, which
displays a clear synaptic junction with
normal abundance of synaptic vesicles
compared with the NMJ of WT mice (Fig-
ure S3). a-Bungarotoxin labeling of the
neuromuscular junction revealed no dif-
ference between WT and SCA17 KI mice
(Figure S4A). Also, immunostaining of spi-
nal cord neurons with antibodies to NeuN
and ChAT revealed no differences be-
tween SCA17 KI and WT mice (Figures
S4B and S4C). All these findings suggest
that mutant TBP is unlikely to causeneuromuscular dysfunction or spinal cord neuronal loss that
leads to muscle atrophy.
To provide more rigorous evidence for the primary effect of
mutant TBP in muscle cells, we crossed floxed SCA17 KI mice
with transgenic mice that express Cre under the control of the
muscle creatine kinase (MCK) promoter, which drives the
expression of Cre selectively in skeletal muscle cells (Bru¨ning
et al., 1998). The expression of mutant TBP in muscles in the
Figure 2. Mutant TBP Induces Muscle Pa-
thology
(A) H&E cross-section staining of tibialis anterior
(TA) muscles from 3-month-old and 7-month-old
SCA17 KI mice showing an age-dependent
decrease in myofibril size, including severe muscle
atrophy (black arrow) and cells containing central
nuclei (white arrow), a feature of muscle degener-
ation. Scale bars, 50 mm.
(B) Quantification of cross-sectional area of myo-
fibrils at indicated ages. Values are mean ± SEM
of data from five mice in each group (**p < 0.01,
n = 500).
(C) Electron microscopy of WT and SCA17 KI TA
muscles. In KI muscle, Z bands are destructed and
mitochondria are swollen, abnormally shaped, and
enlarged. Scale bars, 0.2 mm.crossed (muscle-KI) micewas verified by immunocytochemistry,
which showed that mutant TBP inmuscle-KI mice is restricted to
skeletal muscle cells and is less abundant than in SCA17 KI
muscle, likely due to the fact that mutant TBP is not expressed
in non-muscle cells in muscle-KI mice (Figure 3A). By performing
immunostaining of the brain cortex tissues of WT, SCA17 KI, and
muscle-KImice, we verified thatmutant TBP inmuscle-KI mice is
absent in the brain, whereas SCA17 KI mouse brain displayed
intensive nuclear TBP staining (Figure 3B). High-magnification
micrographs revealed that mutant TBP also formed nuclear ag-
gregates in muscle-KI skeletal myocytes in the same manner
as in the muscle cells of SCA17 KI mice (Figure 3C). Importantly,
we also found degeneration of skeletal muscle cells in the mus-Cell Reports 13, 196–20cle-KI mice, as characterized by multiple
centralized nuclei and atrophic muscle
cells with reduced size (Figures 3D and
3E). Thus, by examining both SCA17 KI
and muscle-KI mouse models, we find
compelling evidence that mutant TBP
expression in skeletal muscle cells can
cause muscle atrophy, pointing to a pri-
mary effect of mutant TBP in peripheral
tissues.
Mutant TBP Weakens Muscle and
Causes Movement Abnormalities
and Early Death
Given the muscle atrophy in SCA17 KI
mice, we wondered whether this periph-
eral pathology might contribute to the
progression of disease and more severe
symptoms. Indeed, SCA17 KI mice
showed age-dependent symptoms, in-
cluding hunchback appearance (Fig-
ure 4A) and reduced body weight (Fig-
ure 4B). Because of the muscle atrophy
in these mice, we tested grip strength,
which reflects the muscle strength of
mouse legs.We found a significant reduc-
tion of grip strength in SCA17 KI mice(Figure 4C). As a result, rotarod performance, which can be
affected by reduced muscle strength, was poor in SCA17 KI
mice (Figure 4C). Also, we detected an abnormal gait in SCA17
KI mice, which reflects both ataxia and muscle atrophy (Figures
4D and 4E). Furthermore, the lifespan of SCA17 KI mice was
shorter than that of WT mice (Figure 4F), indicating that muscle
atrophy makes an important contribution to severe disease
symptoms.
If muscle degeneration does contribute critically to the severe
symptoms of SCA17 KI mice, we should also see similar move-
ment abnormalities in muscle-KI mice. Indeed, muscle-KI mice
at the age of 7 months had a hunchback appearance similar to
SCA17 KI mice (Figure 4G). They also had an age-dependent8, October 6, 2015 ª2015 The Authors 199
Figure 3. Expression of Mutant TBP in Mus-
cle Also Leads to Muscle Degeneration
(A) 1TBP18 staining showing the expression of
mutant TBP in 3-month-old SCA17 KI (KI) and
muscle-KI mouse muscles.
(B) Mutant TBP was detected in the SCA17 KI
brain, but not WT or muscle-KI brain.
(C) High-power magnification (6303) photographs
showing small nuclear aggregates in SCA17 KI
mouse striatum and muscle, as well as muscle-KI
mouse muscle.
(D) H&E cross-sectional staining of TA muscles
from WT, muscle-KI, and neuron-KI (nestin-KI)
mice at indicated ages. Atrophic muscle cells
(black arrow) and cells containing centralized
nuclei (white arrow) are indicated.
(E) Quantification of cross-sectional areas of
myofibrils inWT, neuron-KI, andmuscle-KI skeletal
muscle tissues (n = 500, *p < 0.01; ***p < 0.001).
Scale bars represent 100 mm (A), 20 mm (B),
20 mm (C), and 50 mm (D). Data are presented as
mean ± SEM.reduction in body weight, poor rotarod performance, and
reduced grip strength; moreover, they had a shorter lifespan,
as they died within 1 year (Figure 4H). Comparing our previously
established SCA17mice that expressmutant TBP in the brain via
nestin-Cre (nestin-KI) and the SCA17 KI mice established in this
current study, both SCA17 KI and muscle-KI mice show more
severe phenotypes and earlier onset (3–4 months) than nestin-
KI mice, which experience later (12 months) onset and milder
phenotypes including body weight loss and poor rotarod perfor-
mance, as characterized in our previous studies (Huang et al.,
2011). In addition, both SCA17 KI and muscle-KI mice experi-200 Cell Reports 13, 196–208, October 6, 2015 ª2015 The Authorsence early death (Table S1). Thus, the
expression of TBP in skeletal muscle cells
can cause progressive phenotypes and
leads to the early death of mice.
The late-onsetmuscle degeneration and
symptoms in SCA17 KI mice suggest that
mutant TBP may only affect adult muscle
cells. To validate this idea,wealso crossed
floxedSCA17KImicewith transgenicmice
expressingCre inmuscleprogenitor or sat-
ellite cells, which are able to differentiate to
adult muscle cells, under the control of the
Pax7 promoter. The crossed mice ex-
pressed mutant TBP selectively in muscle
satellite cells that are located between
the basal lamina and sarcolemma of mus-
cle fiber (Figure S5A). These mice, how-
ever, did not show any abnormal growth
and impaired movement compared with
WT mice (Figures S5B and S5C).
Mutant TBP Abnormally Interacts
with MyoD and Reduces Its Level
To investigate the mechanism by which
mutant TBP causes muscle atrophy, wefirst used proteomics for protein profiling. Muscle tissues from
SCA17 KI andWTmice at 6months of agewere isolated for anal-
ysis. Coomassie blue staining of the mouse hindlimb skeletal
muscle tissue samples from WT and SCA17 KI mice revealed a
number of proteins decreased specifically in KI muscles; how-
ever, there were no obvious differences between SCA17 KI
and WT samples in cerebellum tissues (Figure 5A). Mass spec-
trometry, which uncovered 2,493 proteins and 12,310 peptides,
revealed a decrease in the number of muscle-specific proteins,
such as myosin light polypeptide kinases-2, titin isoform N2-A,
and muscle creatine kinase, in SCA17 KI muscle (Figure 5B).
Figure 4. Mutant TBP Causes Phenotypes
Related to Muscle Degeneration
(A) SCA17 KImouse at 6months of age (arrow) was
smaller and poorly groomed relative to WT litter-
mate. Such phenotypes were not seen in SCA17 KI
mice at 3.5 months.
(B) Changes in body weight of KI mice compared
with WT mice (n = 16 each group, sex matched).
(C) Grip strength (upper panel) and non-acceler-
ating rotarod performance (low panel) of KI andWT
mice at 1, 3, and 6 months of age.
(D) Representative walking footprint patterns of
6-month-old WT and KI mice.
(E) Quantification of stride length test showing that
KI mice display shorter strides compared with the
evenly spaced footprints of WT mice (n = 10).
(F) Survival plot showing a reduced lifespan of
SCA17 KI mice relative to WT mice (n = 16 each
group).
(G) The muscle-KI mouse at 7 months of age
(arrow) was smaller and poorly groomed relative to
WT littermates.
(H) From left to right, body weight, non-acceler-
ating rotarod performance, grip strength, and
survival plot showing reduced body weight,
movement deficit, decreased grip strength, and
shortened lifespan of muscle-KI mice compared
with age-matched WT or Neuron-KI (nestin-KI)
mice (n = 16 each group, sex matched). Data are
presented as mean ± SEM.Because TBP is a transcription factor, the decreased expression
of these muscle-specific proteins likely occurs at the transcrip-
tional level. We therefore also performed microarrays for gene
expression profiling in the cerebellum and skeletal muscle of
SCA17 KI and WT mice. We analyzed a total of 35,240 tran-
scripts in SCA17 KI muscle and cerebellum and found more
genes with altered expression in muscle than in the cerebellum
(Tables S2 and S3). Also, more muscle-specific genes were up-
regulated (12) or downregulated (18) than neuronal-specific
genes (2 upregulated, 5 downregulated) (Table S4). qPCR anal-
ysis verified there was a decrease in the mRNA levels of muscle-
specific genes, such as Calc-L, Myo-bpc2, CKM, and Trim72, in
SCA17 KI mouse muscles (Figure 5C).
Muscle-specific gene expression is regulated by a few tran-
scription factors (MyoD, Myf5, myogenin, and MRF4), which
make up the myogenic bHLH transcription factor family andCell Reports 13, 196–20are specifically expressed in skeletal
muscle (Tapscott et al., 1988). We found
that, in SCA17 KI mice, transcripts of
myogenin andMyoDwere increased (Fig-
ure 5C), suggesting that these muscle-
specific transcription factors are upregu-
lated due to the decreased levels of
muscle-specific gene products. We were
able to obtain antibodies to detect
MyoD, Myf5, and myogenin in mouse tis-
sues, so we focused on the expression of
these transcription factors in the skeletal
muscle tissues of SCA17 KI mice. West-ern blotting revealed that only MyoD, but not myogenin, was
decreased in SCA17 KI muscles (Figures 5D and 5E). The
expression of Myf5 appeared to increase in old SCA17 mouse
muscle, perhaps because of a compensatory upregulation
mechanism by the decreased levels of MyoD and muscle-spe-
cific proteins. These results suggest it is the decreased protein
level of MyoD that results in the downregulation of a number of
muscle-specific genes and subsequent muscle degeneration.
PolyQ-Length-Dependent Muscle Degeneration and
Interaction of TBP with MyoD
The striking retarded growth and muscle atrophy are not seen in
SCA17 patients who express 43–55 polyQ TBP repeats. Given
that large repeats (63Q and 66Q) in TBP cause juvenile SCA17
cases and also lead to retarded growth and muscle weakness
phenotypes (Koide et al., 1999; Maltecca et al., 2003), we8, October 6, 2015 ª2015 The Authors 201
Figure 5. Mutant TBP Downregulates Mus-
cle-Specific Protein Expression by Re-
ducing MyoD Protein Level
(A) Coomassie blue staining showing the protein
composition of cerebellum and muscle tissue from
WT and KI mice at 6 months of age. Arrows
indicate proteins that show decreased levels in
SCA17 KI muscles compared with age-matched
WT muscles.
(B) Mass spectrometry analysis identified several
muscle-specific genes that are downregulated in
SCA17 KI muscle.
(C) Relative mRNA expression levels were deter-
mined by quantitative real-time PCR for calcium
channel, voltage-dependent L type, alpha 1S
subunit (Calc-L), myosin-binding protein C, fast
type (Myo-bpc2), creatine kinase, muscle (CKM),
tripartite motif-containing 72 (Trim72), myostatin
(Mstn), myogenin (Myog), and MyoD in the TA
muscle from SCA17 KI mice compared with WT
mice at 3 months of age.
(D) Western blot analysis of MyoD, Myf5, and
myogenin expression in TA muscles of 1-, 3-, and
8-month-old KI and WT mice.
(E) The densitometric ratios of indicated protein to
GAPDH (*p < 0.05, **p < 0.01). Data are presented
as mean ± SEM.assume that a large polyQ repeat in TBP can cause the unique
muscle atrophy phenotype. To test this idea, we generated
AAV vectors that express TBP containing 13Q, 44Q, 68Q, or
98Q and injected them into the tibialis anterior (TA) muscle of
WT mice. One month after injection, muscle histology revealed
mutant TBP with the larger polyQ repeat elicited more severe
muscle degeneration, which is shown by the greater reduction
in the cross-sectional area of muscle fibers and increase in the
percentage of muscle cells with centralized nuclei (Figures 6A
and 6B). Thus, the extent of muscle degeneration depends on
the TBP polyQ repeat length.
We know that the interaction between TBP and MyoD is
required for the transcriptional activity of MyoD (Heller and Ben-
gal, 1998). Thus, it would be important to know whether a large
polyQ repeat can reduce the association of TBP with MyoD to
a greater extent, such that the large polyQ repeat selectively
causes the muscle atrophy phenotype in SCA17. We therefore
examined the association of MyoD with TBP containing different
lengths of the polyQ repeat in transfected HEK293 cells via
immunoprecipitation. We reported previously that polyQ ex-
pansion increases the association of mutant TBP with the
transcription factor nuclear factor-YA (NF-YA) and affects its
transcriptional activity on the expression of chaperone proteins202 Cell Reports 13, 196–208, October 6, 2015 ª2015 The Authorsin neuronal cells (Huang et al., 2011). We
compared the interactions of mutant
TBP with MyoD and NF-YA under the
same immunoprecipitation conditions.
The comparison revealed that the larger
polyQ repeat indeed caused a greater
reduction in the association of TBP with
MyoD, although it increased the bindingof TBP to NF-YA to a great extent (Figures 6C and 6D). Thus,
different polyQ repeats may confer different conformations of
TBP, leading to the differential association of mutant TBP with
other transcription factors.
Large PolyQ Repeats in TBP Affect MyoD Levels
TBP reportedly interacts with MyoD to stabilize its association
with DNA promoter (Heller and Bengal, 1998). We hypothesized
that the large polyQ repeat may decrease the binding of TBP to
MyoD, thereby reducing its association with the DNA promoter
and promoting the degradation of MyoD. To test this hypothe-
sis, we first examined whether the half-life of MyoD is short-
ened in the presence of TBP-105Q because of an accelerating
degradation. Cycloheximide-chase experiments on cultured
C2C12 cells, a muscle cell line, revealed that MyoD was
degraded faster in the presence of mutant TBP (Figures S6A
and S6B). Inhibiting the proteasome with MG132 could in-
crease the level of MyoD in TBP-105Q-transfected cells
(Figure S6C), suggesting that MyoD is cleared out by the ubiq-
uitin-proteasome system. Unlike other interacting proteins that
can be sequestered into nuclear TBP inclusions, MyoD appears
to be diffuse even in the presence of TBP aggregates in
transfected cells, indicating that soluble mutant TBP interacts
Figure 6. PolyQ-Repeat-Length-Dependent Muscle Degeneration and Interactions with Different Transcription Factors
(A) Two-month-old wild-type (WT) mice were injected with AAV viruses encoding TBP with different polyQ lengths (13Q, 44Q, 68Q, and 98Q) into the tibialis
anterior (TA) muscle. One month after injection, TA muscle was collected and stained using H&E. Scale bar, 40 mm.
(B) Cross-sectional area of muscle cells and percentage of muscle cells with centralized nuclei from mice injected with different AAV viruses (n = 10 images per
group, one-way ANOVA; *p < 0.05, **p < 0.01, ***p < 0.001).
(C and D) HEK293 cells were co-transfected with NF-YA (C) or MyoD (D) and TBP with different polyQ lengths (13Q, 44Q, 68Q, and 98Q). A rabbit polyclonal
antibodywas used to pull down NF-YA orMyoD, and 1TBP18 antibody was used to detect TBP in the pull-down lysate. The results were quantified by normalizing
the amount of TBP pulled down to input (n = 3, one-way ANOVA; *p < 0.05). Data are presented as mean ± SEM.
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Figure 7. Mutant TBP with 105Q Causes
MyoD Dysfunction
(A) In vivo ChIP assay examining MyoD occupancy
of the DNA promoters for mouse myosin heavy
chain 4 (MHC4) and mouse muscle creatine kinase
(MCK) in SCA17 KI and WT TA muscle tissues.
Cross-linked chromatin materials were precipi-
tated by anti-MyoD antibody and then subjected to
polymerase chain reaction with primers for the
promoter regions of mouse MHC4 or MCK that
bind MyoD.
(B) Quantification of PCR results from ChIP assays
evaluating MyoD association with DNA promoters
(mean ± SEM, n = 3). ChIP values relative to WT for
theMHC4 andMCK promoters in TAmuscles from
WT and SCA17 KI mice at 3 months of age are
presented (n = 5, **p < 0.01).
(C) H&E cross-section staining of tibialis anterior
(TA) muscles from 3-month-old WT mice, which
had been injected with lentiviral (Lv) Lv-GFP or Lv-
MyoD-shRNA for 45 days. MyoD-shRNA-injected
TA muscle showing a decrease in myofibril size in
the viral-injected area. Quantification of cross-
sectional area of myofibrils that were injected with
Lv-GFP (control) or Lv-MyoD-shRNA. Values are
mean ± SEM of data from five mice in each group.
Values are relative to control cross-sectional area
(*p < 0.05, n = 150).
(D) H&E cross-sectional staining of tibialis anterior
(TA) muscles from 3-month-old WT mice 1.5
months after injection of AAV1-GFP or AAV1-
MyoD, which is under the control of human actin 1
(ACT1) promoter. Scale bars, 40 mm. AAV1-MyoD-
injected TA muscle showing an increase in myofi-
bril size in the viral-injected area compared to the
control side. Quantification of cross-sectional area
of myofibrils (**p < 0.01, n = 500). Values are rela-
tive to the cross-sectional area of control muscle
injected with AAV1-GFP.
(E) Summary cartoon of the effect of the large
polyQ repeat (105Q) on the association of mutant
TBP with MyoD. MyoD normally binds the E-box of
DNA promoters and links with other transcriptional
factors to trigger the expression of muscle-specific
genes. When mutant TBP carries a large polyQ
repeat, its decreased binding to MyoD diminishes
the association of MyoD with DNA promoter and
transcriptional complex, resulting in the reduced
expression of muscle genes and associated mus-
cle atrophy.with MyoD (Figure S6D). Because the association of TBP with
MyoD stabilizes MyoD (Heller and Bengal, 1998) and the large
polyQ repeat reduces this association, the decreased associa-
tion of mutant TBP with MyoD may promote the degradation of
MyoD and reduce its half-life.
We suspected the decreased interaction betweenmutant TBP
and MyoD might affect the association between MyoD and the
DNA promoter to reduce its transcriptional activity. To test this
idea, we performed a chromatin immunoprecipitation (ChIP)
assay that has been widely used to measure DNA-protein
interactions. Compared with normal TBP, mutant TBP indeed
reduced the association between MyoD and the DNA promoter
for the expression of the muscle-specific proteins MHC4 and204 Cell Reports 13, 196–208, October 6, 2015 ª2015 The AuthorsMCK (Figure 7A). Quantification of ChIP assays validated the
decreased association between MyoD and the promoter in the
presence of mutant TBP (Figure 7B).
To test whether MyoD levels are indeed critical for the muscle
atrophy seen in SCA17 mice, we used lentiviral or AAV1 vectors
to suppress MyoD via small interfering RNA (siRNA) or overex-
press MyoD in skeletal muscle tissues by focal injection of these
viral vectors into the skeletal muscle of mouse hind legs. We first
confirmed that the MyoD viruses could alter the expression of
MyoD in themuscle cell line C2C12 (Figures S7A and S7B). These
vectors coexpressed with EGFP or ECFP so the injected muscle
area could be defined (Figure S7C). The expression of lentiviral
siRNA in WT mouse muscle for 1.5 months led to a reduction
in muscle cross-sectional areas, a phenotype similar to muscle
degeneration (Figure 7C). An even more important experiment
was testingwhether overexpression ofMyoDcould alleviatemus-
cle degeneration inSCA17KImice. Thus,mouse skeletalmuscles
were injectedwith AAV1-MyoD for 1.5months, andwe found that,
compared with AAV1-GFP (control) injection, AAV1-MyoD signif-
icantly increased the muscle cross-sectional areas or reduced
muscle degeneration in SCA17 KI mice at 3 months of age (Fig-
ure 7D). Since MyoD binds the E-box sequence (CANNTG) in
promoters of downstream muscle target genes to drive the tran-
scriptionof thesemuscle-relatedgenes incollaborationwithother
transcription factors, we propose that the large polyQ repeat de-
creases the association of TBP with MyoD, thereby weakening
the association between MyoD and DNA, resulting in the reduc-
tion of muscle-specific proteins and causing muscle degenera-
tion, a peripheral phenotype that is specifically mediated by large
polyQ repeats in SCA17 (Figure 7E).
DISCUSSION
One mystery of polyQ neurodegenerative diseases is how large
polyQ repeats in these diseases cause pathology and symp-
toms in juvenile patients that are different from those in adult-
onset patients, who express mutated proteins with intermediate
polyQ expansion, often shorter than 55 glutamines. A typical
example is HD, which is caused by polyQ expansion in the ubiq-
uitously expressed protein huntingtin. Most HD patients carry
42–55 CAG repeats in the HD gene and show symptoms in
the middle of life. Approximately 10 percent of HD cases carry
larger polyQ repeats (>65) and develop symptoms younger
than the age of 20 years. Although both the early- and adult-
onset forms of HD are characterized by dementia, movement
disorder, and personality changes, juvenile HD patients do not
display the chorea seen in adult-onset patients. Instead, juvenile
HD patients are often rigid and stiff and exhibit severe cognitive
dysfunction and seizure that is not seen in adult HD patients
(Vargas et al., 2003; Squitieri et al., 2006). In the brains of juve-
nile HD patients, there are more nuclear aggregates and fewer
neuropil aggregates than in adult HD brains (DiFiglia et al.,
1997; Gutekunst et al., 1998), and also more widespread degen-
eration, suggesting that polyQ repeat lengths mediate different
pathogenic pathways.
Like HD and other polyQ diseases, most SCA17 patients carry
43–48 CAGs in the TBP gene with reduced penetrance or late
age of onset of symptoms. Although these symptoms are char-
acterized as ataxia, dementia, and involuntary movements,
larger repeats (>63 CAG) apparently cause mental deterioration,
gait abnormalities, muscle weakness, and retarded growth at
age 13 or younger (Koide et al., 1999; Maltecca et al., 2003).
The clinical symptoms in juvenile SCA17 patients are similar to
those in SAC17 KI mice, also suggesting that glutamine repeat
length can determine the nature of the pathology in polyQ dis-
eases. It has been reported that a large CAG repeat can produce
polyalanine and polyserine peptides via RAN translation or
repeat associated non-ATG translation (Cleary and Ranum,
2013). However, our conditional SCA17 KI mice do not show
any symptoms and muscle phenotypes when expanded polyQ
repeat expression is prevented by the stop codon, supportingCthe idea that the muscle degeneration is caused by mutant
TBP with expanded polyQ repeats.
The rarity of SCA17 patients has allowed for only limited docu-
mentation of histological examinations from very few postmor-
tem SCA17 patient brains, and the peripheral pathology of
SCA17 patients has gone unreported. By establishing SCA17
KI mice expressing a large polyQ repeat (105Q), we uncovered
strong evidence for muscle degeneration that is apparently
caused by the expression of mutant TBP in muscle cells and
its adverse effect on MyoD. First, we found no evidence for
degeneration of the neuromuscular junction in those SCA17 KI
mice that begin to show muscle degeneration at 3 months of
age. Second, the selective expression of mutant TBP in muscles
in muscle-KI mice also caused muscle degeneration and clinical
phenotypes. Third, direct injection of viral vector expressing
mutant TBP into the mouse muscle tissue led to muscle degen-
eration. Finally, muscle degeneration in SCA17 mice could be
rescued by overexpressing MyoD, amuscle tissue-specific tran-
scription factor.
Several different transgenic SCA17 rodent models expressing
polyQ repeats (64Q, 71Q, and 109Q) have been established and
show age-dependent ataxia phenotypes, with no reports ofmus-
cle atrophy (Chang et al., 2011; Kelp et al., 2013; Portal et al.,
2013). However, these rodentmodels expressmutant TBP under
the control of the neuronal prion promoter (Portal et al., 2013;
Kelp et al., 2013) or the Purkinje-specific protein (Pcp2/L7)
gene promoter (Chang et al., 2011), suggesting that the muscle
degeneration seen in SCA17 requires the expression of mutant
TBP in muscle cells. In support of this idea, our previously estab-
lished SCA17mousemodel, which expressesmutant TBP-105Q
in neuronal cells, does not develop the severe muscle atrophy
and symptoms of SCA17 KI mice (Huang et al., 2011). The mus-
cle phenotype seen in our SCA17 KImice apparently depends on
the expression of TBP with a larger polyQ repeat (105Q). First,
there have been no reports of muscle atrophy or related symp-
toms in adult-onset SCA17 patients who carry polyQ repeats
shorter than 55 glutamines. Second, by expressing TBP contain-
ing different polyQ repeat lengths in mouse skeletal muscle, we
found that only the large repeat induces severe muscle degener-
ation. We suspected the large polyQ repeat could cause a
unique protein conformational change that confers a specific
gain or loss function to TBP. To test this idea, we compared
the interactions of mutant TBP containing different polyQ re-
peats with the neuronal transcription factor NF-YA and the mus-
cle transcription factor MyoD. The comparison shows that the
large polyQ repeat can increase the interaction of mutant TBP
with NF-YA but reduces the interaction of TBP with MyoD. This
finding provides a biochemical basis to explain why the large
polyQ repeat in TBP can induce unique pathological changes
in the peripheral tissues thatmay hardly be seen in adult patients,
who carry mutant TBP with shorter expanded polyQ repeats.
Our studies identified MyoD as an important target in SCA17
muscle atrophy. MyoD is believed to be activated during muscle
cell differentiation and regeneration (Hawke and Garry, 2001).
Yet despite its critical role in muscle differentiation, genetic
depletion of the mouse MyoD gene does not lead to obvious
muscle atrophy in mice (Rudnicki et al., 1992). Muscle genesis
and differentiation during early embryonic stages are controlledell Reports 13, 196–208, October 6, 2015 ª2015 The Authors 205
by different transcription factors; the basic helix-loop-helix
myogenic regulatory factors MyoD, Myf5, myogenin, and
MRF4 play critical roles in skeletal muscle development. After
muscle cell fibers have formed, MyoD in satellite cells is thought
to be activated only during the regeneration of muscle cells or in
response to muscle injury (Hawke and Garry, 2001). In addition,
MyoD is present in myotubes, and its level in myotubes is critical
for maintaining muscle size and regeneration (Dedkov et al.,
2003; Ishido et al., 2004; Legerlotz and Smith, 2008; Tanaka
et al., 2008; Andrews et al., 2010). Myogenesis is known to
require switching of the core promoter recognition complex,
TFIID, and MyoD targets specific TBP-associated factor (TAF3)
and TBP-related factor (TRF3) to activatemyogenin transcription
(Deato and Tjian, 2007; Deato et al., 2008). Although little is
known about the function of MyoD and its relationship with
TBP in adult muscle cells, our studies suggest that mutant TBP
affects muscle only in adult mice. This is because our SCA17
mice, like juvenile SCA17 patients with 63Q or 66Q in TBP (Koide
et al., 1999; Maltecca et al., 2003), are born normally without
muscle weakness, with muscle degeneration occurring several
months later. Mutant TBP accumulates in muscle nuclei and be-
comes misfolded with age, consistent with its late-onset effect
on MyoD function in adult muscles.
TBP levels are tightly regulated, since floxed SCA17 KI mice,
which express one copy of the normal TBP gene, or are equiva-
lent to heterozygous TBP knockout mice, show the same levels
of normal TBP as WT TBP mice, which carry two copies of the
normal TBP gene (Friedman et al., 2007, 2008; Yang et al.,
2014). Similarly, in SCA17 KI mouse brain and muscle, express-
ing one copy of mutant TBP can downregulate the level of
endogenous normal TBP (Figures 1 and S1). This fact suggests
that while mutant TBP preserves some important normal func-
tions during early development, it can cause a gain of toxic func-
tion and also reduces the level of normal TBP to induce a loss of
function of normal TBP. TBP is known to interact with MyoD to
stabilize its association with DNA promoter (Heller and Bengal,
1998), and the stability ofMyoD is critical formuscle cell function.
For example, TNF-adestabilizesMyoD and induces apoptosis of
muscle cells (Degens, 2010). In adult muscle cells, when polyQ
expansion in TBP reduces its association with MyoD and when
normal TBP is also decreased because of the expression of
mutant TBP, more MyoD is likely to dissociate from a protein-
DNA complex and then be subjected to degradation by the ubiq-
uitin-proteasome system. The delicate regulation of MyoD by
TBP may explain the specific role of TBP in muscle cells and
the adverse effect of mutant TBP on gene transcription in muscle
cells. Because of its low level in myotubes, the function of MyoD
in adult muscle cells may be particularly vulnerable to mutant
TBP, especially when the function of TBP is affected by a large
glutamine repeat.
There are differing extents of muscle atrophy in various polyQ
diseases. SBMA is characterized by adult-onset muscle weak-
ness and lower motor neuron degeneration, and transgenic
mouse models of SBMA also show that muscle atrophy can be
caused by the expression of mutant protein in muscle (Cortes
et al., 2014; Lieberman et al., 2014). HD mouse models also
show muscle atrophy at the late disease stages, which may be
caused by defective energy metabolism and oxidation associ-206 Cell Reports 13, 196–208, October 6, 2015 ª2015 The Authorsated with the re-expression of the HDAC4-DACH2-myogenin
axis (Mielcarek et al., 2015). The muscle atrophy in our SCA17
KI mice indicates that a large polyQ expansion in TBP selectively
alters its specific function to affect MyoD in muscle cells.
Because this dysfunction is dependent on the length of the polyQ
repeat in TBP, our findings suggest that polyQ repeat lengths
can differentially alter the function of the polyQ proteins, offering
an explanation for the differential pathology and symptoms in
adult-onset and early-onset polyQ diseases, which are caused
by different polyQ repeat lengths. Also, characterization of ani-
mal models expressing large polyQ repeats should not be limited
to the brain and needs to consider the possible peripheral pa-
thology. Moreover, our findings also suggest that the treatment
of juvenile polyQ diseases involving large polyQ repeats should
take into account the widespread and severe pathology that
may occur in peripheral tissues.
EXPERIMENTAL PROCEDURES
Mice
All mice were bred and maintained in the animal facility at Emory University
under specific-pathogen-free conditions in accordance with institutional
guidelines of the Institutional Animal Care and Use Committee at Emory Uni-
versity. The TBP105Q floxed mice and TBPKI-NestinCre mice were gener-
ated as described before (Huang et al., 2011). To generate germline KI
mice, heterozygous TBP105Q floxed mice were crossed with EIIa-Cre trans-
genic mice (The Jackson Laboratory, B6.FVB-Tg (EIIa-Cre) C5379Lmgd/J);
this line carries a Cre transgene under the control of the adenovirus EIIa pro-
moter that targets expression of Cre recombinase to the early mouse em-
bryo. Cre-mediated recombination occurs in a wide range of tissues,
including the germ cells that transmit the genetic alteration to progeny.
To generate muscle TBP KI mice, heterozygous TBP105Q floxed mice
were crossed with CKmm-Cre transgenic mice (The Jackson Laboratory,
B6.FVB (129S4)-Tg(Ckmm-cre) 5Khn/J). These transgenic mice have the
Cre recombinase gene driven by the muscle creatine kinase (MCK or Ckm)
promoter. Cre activity is observed in skeletal and cardiac muscle. When
bred with mice containing a loxP-flanked mutant TBP sequence, Cre-medi-
ated recombination will result in skeletal and cardiac muscle turn-on of the
mutant TBP gene. TBP105Q floxed mice were also crossed with Pax7-Cre
mice (The Jackson Laboratory, B6;129-Pax7tm1(cre)Mrc/J) to generate
mice that express TBP105Q in muscle satellite cells. Primers used for geno-
typing were as follows: for mutant TBP, forward: 50-CCA CAG CCT ATT CAG
AAC ACC-30; reverse: 50-AGA AGC TGG TGT GGC AGG AGT GAT-30; for
Cre, forward 50-GCG GTC TGG CAG TAA AAA CTA TC-30; reverse: 50-TGT
TTC ACT ATC CAG GTT ACG G-30.
Collection of Muscles and Morphometric Measurements
Mice were sacrificed, and TA muscles were removed, embedded in OCT
mounting medium, and frozen in 2-methybutane cooled in liquid nitrogen.
Serial cross-sections were collected onto gelatin-subbed slides at 400- to
500-mm intervals along the entire length of the muscle and analyzed histolog-
ically by H&E staining. Serial 15-mm sections were collected along the entire
length of the muscle and stained with H&E. Analyses and photography were
performed using a Zeiss Axioplan microscope equipped with a video camera
and AxioVision Rel. 4.8 software. To quantitatively analyze cross-sectional
area, we used imaging software ImageJ (NIH). The cross-sectional area is
determined in the muscle belly, and anatomical landmarks of each muscle
were used to find the same region in different samples.
Statistical Analysis
Results generated from three ormore independent experiments are expressed
as the mean ± SD and were analyzed for statistical significance using
GraphPad Prism 5 software. Statistical significances were calculated based
on t tests, and a p value < 0.05 was considered significant.
ACCESSION NUMBERS
The accession number for the microarray data reported in this paper is GEO:
GSE72176.
SUPPLEMENTAL INFORMATION
Supplemental information includes Supplemental Experimental Procedures,
seven figures, and four tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.08.060.
AUTHOR CONTRIBUTIONS
S.H., S. Yang, S.L., and X.-J.L. designed research. S.H. and S. Yang per-
formed experiments. S.H., S. Yang, S.L., and X.-J.L. analyzed the data and
wrote the manuscript. J.G. and S. Yan assisted with generating reagents.
M.A.G. assisted with mouse breeding.
ACKNOWLEDGMENTS
This work was supported by NIH grants AG019206 and NS041449 (to X.-J.L.)
and NS095279 and NS0405016 (to S.H.). This research project was supported
in part by the Viral Vector Core of the Emory Neuroscience NINDS Core Facil-
ities grant P30NS055077. We thank Heju Zhang at the Transgenic Mouse and
Gene Targeting core at Emory for generating the TBP floxed mouse line, Duc
M. Duong and Nicholas T. Seyfried at ENNCF Proteomics Core at Emory Uni-
versity for mass spectrometry analysis, Yi Hong at Robert P. Apkarian Inte-
grated Electron Microscopy Core for electron microscopy analysis, Lin Mei
at Georgia Health Sciences University for providing C2C12 cells and the hu-
man ACT1 promoter, Grace K. Pavlath for advice, Benjamine J. Redpath
and Naureen Mith for technical assistance, and Cheryl Strauss for critical
reading of this manuscript.
Received: May 3, 2015
Revised: July 23, 2015
Accepted: August 21, 2015
Published: September 17, 2015
REFERENCES
Andrews, J.L., Zhang, X., McCarthy, J.J., McDearmon, E.L., Hornberger, T.A.,
Russell, B., Campbell, K.S., Arbogast, S., Reid, M.B., Walker, J.R., et al.
(2010). CLOCK and BMAL1 regulate MyoD and are necessary for maintenance
of skeletal muscle phenotype and function. Proc. Natl. Acad. Sci. USA 107,
19090–19095.
Bauer, P., Laccone, F., Rolfs, A., Wu¨llner, U., Bo¨sch, S., Peters, H., Liebscher,
S., Scheible, M., Epplen, J.T., Weber, B.H., et al. (2004). Trinucleotide repeat
expansion in SCA17/TBP in white patients with Huntington’s disease-like
phenotype. J. Med. Genet. 41, 230–232.
Bruni, A.C., Takahashi-Fujigasaki, J., Maltecca, F., Foncin, J.F., Servadio, A.,
Casari, G., D’Adamo, P., Maletta, R., Curcio, S.A., DeMichele, G., et al. (2004).
Behavioral disorder, dementia, ataxia, and rigidity in a large family with TATA
box-binding protein mutation. Arch. Neurol. 61, 1314–1320.
Bru¨ning, J.C., Michael, M.D., Winnay, J.N., Hayashi, T., Ho¨rsch, D., Accili, D.,
Goodyear, L.J., and Kahn, C.R. (1998). A muscle-specific insulin receptor
knockout exhibits features of the metabolic syndrome of NIDDM without
altering glucose tolerance. Mol. Cell 2, 559–569.
Chang, Y.C., Lin, C.Y., Hsu, C.M., Lin, H.C., Chen, Y.H., Lee-Chen, G.J., Su,
M.T., Ro, L.S., Chen, C.M., and Hsieh-Li, H.M. (2011). Neuroprotective effects
of granulocyte-colony stimulating factor in a novel transgenic mouse model of
SCA17. J. Neurochem. 118, 288–303.
Cleary, J.D., and Ranum, L.P. (2013). Repeat-associated non-ATG (RAN)
translation in neurological disease. Hum. Mol. Genet. 22, R45–R51.
Cortes, C.J., Ling, S.C., Guo, L.T., Hung, G., Tsunemi, T., Ly, L., Tokunaga, S.,
Lopez, E., Sopher, B.L., Bennett, C.F., et al. (2014). Muscle expression ofCmutant androgen receptor accounts for systemic and motor neuron disease
phenotypes in spinal and bulbar muscular atrophy. Neuron 82, 295–307.
Deato, M.D., and Tjian, R. (2007). Switching of the core transcription machin-
ery during myogenesis. Genes Dev. 21, 2137–2149.
Deato, M.D., Marr, M.T., Sottero, T., Inouye, C., Hu, P., and Tjian, R. (2008).
MyoD targets TAF3/TRF3 to activate myogenin transcription. Mol. Cell 32,
96–105.
Dedkov, E.I., Kostrominova, T.Y., Borisov, A.B., and Carlson, B.M. (2003).
MyoD and myogenin protein expression in skeletal muscles of senile rats.
Cell Tissue Res. 311, 401–416.
Degens, H. (2010). The role of systemic inflammation in age-related muscle
weakness and wasting. Scand. J Med. Sci. Sports 20, 28–38.
Di Marco, S., Mazroui, R., Dallaire, P., Chittur, S., Tenenbaum, S.A., Radzioch,
D., Marette, A., and Gallouzi, I.E. (2005). NF-kappa B-mediated MyoD decay
during muscle wasting requires nitric oxide synthase mRNA stabilization,
HuR protein, and nitric oxide release. Mol. Cell. Biol. 25, 6533–6545.
DiFiglia, M., Sapp, E., Chase, K.O., Davies, S.W., Bates, G.P., Vonsattel, J.P.,
and Aronin, N. (1997). Aggregation of huntingtin in neuronal intranuclear inclu-
sions and dystrophic neurites in brain. Science 277, 1990–1993.
Friedman,M.J., Shah, A.G., Fang, Z.H., Ward, E.G., Warren, S.T., Li, S., and Li,
X.J. (2007). Polyglutamine domain modulates the TBP-TFIIB interaction: impli-
cations for its normal function and neurodegeneration. Nat. Neurosci. 10,
1519–1528.
Friedman, M.J., Wang, C.E., Li, X.J., and Li, S. (2008). Polyglutamine ex-
pansion reduces the association of TATA-binding protein with DNA and
induces DNA binding-independent neurotoxicity. J. Biol. Chem. 283, 8283–
8290.
Gutekunst, C.A., Li, S.H., Yi, H., Ferrante, R.J., Li, X.J., and Hersch, S.M.
(1998). The cellular and subcellular localization of huntingtin-associated pro-
tein 1 (HAP1): comparison with huntingtin in rat and human. J. Neurosci. 18,
7674–7686.
Guttridge, D.C., Mayo, M.W., Madrid, L.V., Wang, C.Y., and Baldwin, A.S., Jr.
(2000). NF-kappaB-induced loss of MyoD messenger RNA: possible role in
muscle decay and cachexia. Science 289, 2363–2366.
Hawke, T.J., and Garry, D.J. (2001). Myogenic satellite cells: physiology tomo-
lecular biology. J. Appl. Physiol. (1985) 91, 534–551.
Heller, H., and Bengal, E. (1998). TFIID (TBP) stabilizes the binding of MyoD to
its DNA site at the promoter and MyoD facilitates the association of TFIIB with
the preinitiation complex. Nucleic Acids Res. 26, 2112–2119.
Holzenberger, M., Lenzner, C., Leneuve, P., Zaoui, R., Hamard, G., Vaulont,
S., and Bouc, Y.L. (2000). Cre-mediated germline mosaicism: a method
allowing rapid generation of several alleles of a target gene. Nucleic Acids
Res. 28, E92.
Huang, S., Ling, J.J., Yang, S., Li, X.J., and Li, S. (2011). Neuronal expression
of TATA box-binding protein containing expanded polyglutamine in knock-in
mice reduces chaperone protein response by impairing the function of nuclear
factor-Y transcription factor. Brain 134, 1943–1958.
Ishido, M., Kami, K., and Masuhara, M. (2004). In vivo expression patterns of
MyoD, p21, and Rb proteins in myonuclei and satellite cells of denervated
rat skeletal muscle. Am. J. Physiol. Cell Physiol. 287, C484–C493.
Kelp, A., Koeppen, A.H., Petrasch-Parwez, E., Calaminus, C., Bauer, C., Por-
tal, E., Yu-Taeger, L., Pichler, B., Bauer, P., Riess, O., and Nguyen, H.P. (2013).
A novel transgenic rat model for spinocerebellar ataxia type 17 recapitulates
neuropathological changes and supplies in vivo imaging biomarkers.
J. Neurosci. 33, 9068–9081.
Koide, R., Kobayashi, S., Shimohata, T., Ikeuchi, T., Maruyama, M., Saito, M.,
Yamada, M., Takahashi, H., and Tsuji, S. (1999). A neurological disease
caused by an expanded CAG trinucleotide repeat in the TATA-binding protein
gene: a new polyglutamine disease? Hum. Mol. Genet. 8, 2047–2053.
Lakso, M., Pichel, J.G., Gorman, J.R., Sauer, B., Okamoto, Y., Lee, E., Alt,
F.W., andWestphal, H. (1996). Efficient in vivomanipulation of mouse genomic
sequences at the zygote stage. Proc. Natl. Acad. Sci. USA 93, 5860–5865.ell Reports 13, 196–208, October 6, 2015 ª2015 The Authors 207
Legerlotz, K., and Smith, H.K. (2008). Role of MyoD in denervated, disused,
and exercised muscle. Muscle Nerve 38, 1087–1100.
Lieberman, A.P., Yu, Z., Murray, S., Peralta, R., Low, A., Guo, S., Yu, X.X.,
Cortes, C.J., Bennett, C.F., Monia, B.P., et al. (2014). Peripheral androgen re-
ceptor gene suppression rescues disease in mouse models of spinal and
bulbar muscular atrophy. Cell Rep. 7, 774–784.
Lim, J., Crespo-Barreto, J., Jafar-Nejad, P., Bowman, A.B., Richman, R., Hill,
D.E., Orr, H.T., and Zoghbi, H.Y. (2008). Opposing effects of polyglutamine
expansion on native protein complexes contribute to SCA1. Nature 452,
713–718.
Maltecca, F., Filla, A., Castaldo, I., Coppola, G., Fragassi, N.A., Carella, M.,
Bruni, A., Cocozza, S., Casari, G., Servadio, A., and De Michele, G. (2003).
Intergenerational instability and marked anticipation in SCA-17. Neurology
61, 1441–1443.
Mielcarek, M., Toczek, M., Smeets, C.J., Franklin, S.A., Bondulich, M.K., Joli-
non, N., Muller, T., Ahmed, M., Dick, J.R., Piotrowska, I., et al. (2015). HDAC4-
myogenin axis as an important marker of HD-related skeletal muscle atrophy.
PLoS Genet. 11, e1005021.
Nakamura, K., Jeong, S.Y., Uchihara, T., Anno, M., Nagashima, K., Naga-
shima, T., Ikeda, S., Tsuji, S., and Kanazawa, I. (2001). SCA17, a novel auto-
somal dominant cerebellar ataxia caused by an expanded polyglutamine in
TATA-binding protein. Hum. Mol. Genet. 10, 1441–1448.
Orr, H.T., and Zoghbi, H.Y. (2007). Trinucleotide repeat disorders. Annu. Rev.
Neurosci. 30, 575–621.
Portal, E., Riess, O., and Nguyen, H.P. (2013). Automated home cage assess-
ment shows behavioral changes in a transgenic mousemodel of spinocerebel-
lar ataxia type 17. Behav. Brain Res. 250, 157–165.
Rolfs, A., Koeppen, A.H., Bauer, I., Bauer, P., Buhlmann, S., Topka, H., Scho¨ls,
L., and Riess, O. (2003). Clinical features and neuropathology of autosomal
dominant spinocerebellar ataxia (SCA17). Ann. Neurol. 54, 367–375.208 Cell Reports 13, 196–208, October 6, 2015 ª2015 The AuthorsRudnicki, M.A., Braun, T., Hinuma, S., and Jaenisch, R. (1992). Inactivation of
MyoD in mice leads to up-regulation of the myogenic HLH gene Myf-5 and re-
sults in apparently normal muscle development. Cell 71, 383–390.
Squitieri, F., Ciarmiello, A., Di Donato, S., and Frati, L. (2006). The search for
cerebral biomarkers of Huntington’s disease: a review of genetic models of
age at onset prediction. Eur. J. Neurol. 13, 408–415.
Tanaka, Y., Yamaguchi, A., Fujikawa, T., Sakuma, K., Morita, I., and Ishii, K.
(2008). Expression of mRNA for specific fibroblast growth factors associates
with that of the myogenic markers MyoD and proliferating cell nuclear antigen
in regenerating and overloaded rat plantaris muscle. Acta Physiol. (Oxf.) 194,
149–159.
Tapscott, S.J. (2005). The circuitry of a master switch: Myod and the regulation
of skeletal muscle gene transcription. Development 132, 2685–2695.
Tapscott, S.J., Davis, R.L., Thayer, M.J., Cheng, P.F., Weintraub, H., and Las-
sar, A.B. (1988). MyoD1: a nuclear phosphoprotein requiring a Myc homology
region to convert fibroblasts to myoblasts. Science 242, 405–411.
Toyoshima, Y., Yamada, M., Onodera, O., Shimohata, M., Inenaga, C., Fujita,
N., Morita, M., Tsuji, S., and Takahashi, H. (2004). SCA17 homozygote
showing Huntington’s disease-like phenotype. Ann. Neurol. 55, 281–286.
Vannini, A., and Cramer, P. (2012). Conservation between the RNApolymerase
I, II, and III transcription initiation machineries. Mol. Cell 45, 439–446.
van Roon-Mom, W.M., Reid, S.J., Faull, R.L., and Snell, R.G. (2005). TATA-
binding protein in neurodegenerative disease. Neuroscience 133, 863–872.
Vargas, A.P., Carod-Artal, F.J., Bomfim, D., Va´zquez-Cabrera, C., and Dantas-
Barbosa, C. (2003). Unusual early-onset Huntingtons disease. J. Child Neurol.
18, 429–432.
Yang, S., Huang, S., Gaertig, M.A., Li, X.J., and Li, S. (2014). Age-dependent
decrease in chaperone activity impairs MANF expression, leading to Purkinje
cell degeneration in inducible SCA17 mice. Neuron 81, 349–365.
